[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363336-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363336-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fibroblast-mediated-kras-activation-in-double-negative-prostate-cancer","Fibroblast-mediated KRAS activation in double-negative prostate cancer","","Androgen receptor (AR) suppression can inhibit prostate cancer progression, yet many patients relapse and develop castration-resistant prostate cancer (CRPC). Double-negative CRPC (DNPC), lacking both AR and neuroendocrine activity, is increasing but lacks effective therapies. This study shows KRAS minimally influences AR-dependent stages yet strongly activates cancer cells upon AR signaling suppression, driven by AR-mediated changes in fibroblast growth factor receptor expression and stromal CCL2-FGF8b signaling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fibroblast-mediated-kras-activation-in-double-negative-prostate-cancer/363336/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fibroblast-mediated-kras-activation-in-double-negative-prostate-cancer/363336.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are AR signaling inhibitors insufficient for treating prostate cancer long term?","Question",{"text":63,"@type":64},"Although AR signaling suppression improves outcomes, tumors often relapse and progress to castration-resistant prostate cancer (CRPC), eventually becoming independent of AR and resistant to AR signaling inhibitors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does KRAS play in double-negative CRPC progression?",{"text":68,"@type":64},"KRAS shows minimal influence during AR-dependent stages but significantly activates cancer cells when AR signaling is suppressed, and this KRAS activation contributes to DNPC progression.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the study link stromal signaling to KRAS activation?",{"text":72,"@type":64},"AR inhibition alters fibroblast growth factor receptor expression in prostate cancer cells. AR-inhibited cancer cells secrete CCL2, which induces stromal FGF8b secretion in the tumor microenvironment, enhancing KRAS activation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363336,1790211235,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nFibroblast-mediated KRAS activation in double-negative prostate cancer  \nTaiki Kamijima 1, Kouji Izumi 1 ✉, Kaoru Hiratsuka 1, Takahiro Inaba1, Yoshiki Koketsu1, Ryunosuke Nakagawa 1, Ren Toriumi1, Shuhei Aoyama1, Hiroshi Kano1, Tomoyuki Makino1, Renato Naito1, Suguru Kadomoto1, Hiroaki Iwamoto 1, Hiroshi Yaegashi 1, Shohei Kawaguchi 1, Takahiro Nohara1, Kazuyoshi Shigehara1, Hiroki Nakata2, Yohei Saito3, Kyoko Nakagawa-Goto3, Wen-Jye Lin4 and Atsushi Mizokami 1  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | When androgen receptor (AR) signaling is suppressed, prostate cancer progression is inhibited; however, many patients eventually relapse, developing castration-resistant prostate cancer (CRPC). Recently, the incidence of double-negative CRPC (DNPC)—which lacks AR and neuroendocrine activity—has increased, yet effective treatments remain unavailable. Our research demonstrated that KRAS has minimal inﬂuence during the AR-dependent stages of prostate cancer but signiﬁcantly activates cancer cells when AR signaling is suppressed. Further investigation revealed that AR inhibition modiﬁes ﬁbroblast growth factor receptor expression in prostate cancer cells. Additionally, CCL2, secreted by AR-inhibited prostate cancer cells, induces FGF8b secretion from stromal cells within the tumor microenvironment, which in turn enhances KRAS activation. A pan-KRAS inhibitor effectively suppressed AR-independent prostate cancer cells by disrupting KRAS-mediated cell survival signaling. This inhibition led to the signiﬁcant induction of programmed cell death, characterized by the downregulation of the anti-apoptotic protein BCL-xL and the promotion of apoptosis as evidenced by increased cleaved caspase-3 in vivo. These ﬁndings highlight KRAS activation, driven by the CRPC microenvironment, as a critical factor |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| in DNPC progression and identify the induction of KRAS-targeted cell death as a promising therapeutic strategy for DNPC. |  |  |\n|  | Cell Death and Disease (2026)17:403; [https://doi.org/10.1038/s41419-026-08800-3](https://doi.org/10.1038/s41419-026-08800-3) |  |\n|  |  |  |\n\nINTRODUCTION  \nProstate cancer is the most common cancer among men and ranks as the second leading cause of cancer-related deaths [1] . Prostate cancer cells are highly reliant on androgens and are treated by suppressing androgen receptor (AR) signaling [2] . Nevertheless, many patients eventually relapse, resulting in the development of castration-resistant prostate cancer (CRPC) . In CRPC, AR remains active through alternative activation pathways, necessitating the use of more potent secondary therapies to inhibit AR signaling. Recently, second-generation AR signaling inhibitors (ARSIs) have been introduced, which have signiﬁcantly enhanced the prognosis for prostate cancer patients [3–7] . Despite these advancements, CRPC ultimately develops resistance to ARSIs and, in most cases, transitions to a state entirely independent of AR [8] . The mechanisms that sustain prostate cancer cell growth in the absence of AR remain poorly understood. Double-negative CRPC (DNPC), deﬁned by the absence of AR-driven prostate-speciﬁc antigen (PSA) expression and neuroendocrine differentiation (NED), is characterized by local prostate regrowth [9–11] and has no established treatments, leading to a poor prognosis. FGF [12, 13], HGF [14], and CCL2 [15] have been associated with DNPC, though the precise cause remains uncertain. Comprehensive cancer genomic  \nproﬁling identiﬁed KRAS gene aberrations in DNPC patients. However, unlike lung and colon cancers, KRAS alterations are rare in prostate cancer. We hypothesized that canonical KRAS activation could be associated with DNPC, given that ﬁbroblast growth factor receptor (FGFR) serves as a critical upstream regulator of KRAS. Additionally, prosta","cbCaibuVCGwWsMkD","https://ap.wps.com/l/cbCaibuVCGwWsMkD","pdf",5598123,15,"English","# Introduction\n# Materials and Methods\n## Sex as a biological variable\n## Antibodies, recombinant proteins, and chemicals\n## Cell culture","[{\"question\":\"Why are AR signaling inhibitors insufficient for treating prostate cancer long term?\",\"answer\":\"Although AR signaling suppression improves outcomes, tumors often relapse and progress to castration-resistant prostate cancer (CRPC), eventually becoming independent of AR and resistant to AR signaling inhibitors.\"},{\"question\":\"What role does KRAS play in double-negative CRPC progression?\",\"answer\":\"KRAS shows minimal influence during AR-dependent stages but significantly activates cancer cells when AR signaling is suppressed, and this KRAS activation contributes to DNPC progression.\"},{\"question\":\"How does the study link stromal signaling to KRAS activation?\",\"answer\":\"AR inhibition alters fibroblast growth factor receptor expression in prostate cancer cells. AR-inhibited cancer cells secrete CCL2, which induces stromal FGF8b secretion in the tumor microenvironment, enhancing KRAS activation.\"}]","Fibroblast-mediated KRAS activation in double-negative prostate cancer | PDF",1790150845,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1332fb33634353280e2fa3168062e6d4.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/deb8b0b6563c8805043f7d4a29d0d05d.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4944f20ea56d83bddc1e8b35d524c8a1.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3854691e9e8a6cbfc5436d2f4bcda683.webp",980,1301]